Having participated as a clinical investigator in several of the clinical trials of finasteride for male pattern alopecia, I would like to take issue with several points raised in a recent commentary by Dr Sherman Frankel1 published in the ARCHIVES. I would specifically like to address 3 points:
In collaborating with investigators at Merck, I have been impressed with the diligence with which studies were conducted to assure the efficacy and safety of the 1-mg finasteride dose in the treatment of male pattern alopecia.
Thiboutot D. Propecia Dosages. Arch Dermatol. 1999;135(11):1417. doi:10-1001/pubs.Arch Dermatol.-ISSN-0003-987x-135-11-dlt1199